FDA: Johnson & Johnson COVID-19 vaccine tied to Guillain-Barré syndrome

FDA: Johnson & Johnson COVID-19 vaccine tied to Guillain-Barré syndrome

The FDA has said that Johnson & Johnson’s COVID-19 vaccine may lead to an increased risk for Guillain-Barré syndrome.The New York Times reported on July 12 that officials identified 100 suspected cases of Guillain-Barré syndrome, a neurological condition in which the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis, that were linked to the vaccine. Among them, 95% were deemed “serious and required hospitalization.”According to the FDA, in most instances, the symptoms of Guillain Barré syndrome beganRead More

Share on facebook
Share on twitter
Share on linkedin